Morphology-led tumour diagnosis supported by immunohistochemistry, predictive biomarkers and molecular studies.
We provide integrated evaluation of solid and haematolymphoid malignancies, beginning with accurate morphology and adding ancillary testing to refine lineage, classification, prognosis and treatment relevance.
Services are selected and reported in the clinical context, with additional or referral testing advised when appropriate.
Morphology and biomarkers are interpreted together rather than as isolated results.
Ancillary tests are chosen to resolve the differential or answer a treatment-relevant question.
Complex cases can be discussed for specimen planning and staged investigation.
Our laboratory team can guide specimen requirements, timing and available investigations.
